腦腫瘤藥物市場：按適應症、治療方法、通路和地區分類

Brain Cancer Therapeutics Market, By Indication, By Treatment Type, By Distribution Channel, By Geography

出版日期: 2026年06月23日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

據估計，2026年腦瘤治療市場規模為40.52億美元，預計2033年將達到77.963億美元。預計2026年至2033年，該市場將以9.8%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	40.52億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	9.80%	2033年市場規模預測：	77.963億美元

癌症是最常見且最致命的慢性疾病之一。在我們的一生中，體內健康的細胞會以一種受控的方式分裂和更新。當細胞發生異常並開始不受控制地增生時，癌症就會發生。當這些異常細胞生長並形成腫塊時，就形成了腫瘤。癌細胞增生並形成腫瘤，會干擾大腦功能，例如肌肉控制、記憶、感覺和其他正常的身體功能。腦癌的症狀各不相同，但通常包括虛弱、行走困難、頭暈、癲癇發作和頭痛。

大腦和脊髓構成中樞神經系統（CNS），控制所有重要的生理功能，包括思考、運動和語言。因此，如果中樞神經系統出現腫瘤，就會影響患者的思考、運動和語言能力。腦腫瘤的治療方案會根據每位患者的具體情況量身訂做。治療方案由腦腫瘤專家製定，並會因癌症類型、腫瘤在腦內的位置和大小、患者的年齡以及整體健康狀況而有所不同。此外，患者的意願也是決定治療方案的重要因素。

市場動態

預計在預測期內，新型腦腫瘤療法的推出和法規核准的增加將推動市場成長。例如，2020年6月，美國食品藥物管理局（FDA）授予TVAX Biomedical公司用於治療多形性膠質母細胞瘤的過繼性T細胞療法TVI-Brain-1簡審類。 TVI-Brain-1（TVAX Biomedical）是自體疫苗增強型過繼性T細胞療法，包含一種專有的疫苗預處理方法，用於生成癌細胞特異性T細胞，並激活抗腫瘤T細胞療法。此簡審類是基於廣泛的臨床前研究和I期安全性研究，以及II期臨床試驗的積極數據。

本次調查的主要特點

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本報告根據以下參數介紹了全球腦腫瘤治療市場主要參與者的概況：公司概況、產品系列、主要亮點、財務表現和策略。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份「全球腦腫瘤治療市場」報告的目標對象包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師等行業相關人員相關者。
相關人員可以透過利用分析全球腦腫瘤治療市場中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 法國
- 義大利
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第8章競爭情勢

熱圖分析
市佔率分析
- Amgen Inc.
- AstraZeneca PLC
- Hoffmann-La Roche Ltd.
- Pfizer Inc.
- GlaxoSmithKline PLC
- Novartis AG
- Johnson & Johnson
- Merck & Co
- Bayer AG
- Bristol-Myers Squibb Company

第9章

調查方法
關於本公司

簡介目錄

Product Code: CMI4769

Brain Cancer Therapeutics Market is estimated to be valued at USD 4,052 Mn in 2026 and is expected to reach USD 7,796.3 Mn by 2033, growing at a compound annual growth rate (CAGR) of 9.8% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 4,052 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	9.80%	2033 Value Projection:	USD 7,796.3 Mn

Cancer is one of the most prevalent and fatal chronic disorders with a high mortality rate. Throughout our lives, healthy cells in our bodies divide and replace themselves in a controlled fashion. Cancer starts when a cell is altered and it multiplies out of control. A tumor is formed when such abnormal cells grow to form a mass. Cancer cells grow to form tumor that interfere with brain functions such as muscle control, memory, sensation, and other normal bodily functions. Symptoms of brain cancer vary but often include weakness, difficulty walking, dizziness, seizures, and headaches.

The brain and spinal column make up the central nervous system (CNS), where all important functions are controlled. These functions include thought, body movements, and speech. This means that when a tumor grows in the CNS, it can affect a person's thought processes or the way they move or talk. A treatment plan is individualized and planned for each brain cancer patient depending on certain factors. The treatment plan is constructed by the doctors who are specialized in brain cancer, and treatments vary widely depending on the type of cancer, brain location of the tumor, tumor size, patient age, and the general health status of the patient. A major part of the plan is also determined by the wish of the patient.

Market Dynamics

The increasing launches of new drugs and regulatory approvals for brain cancer therapeutics are expected to drive the market growth during the forecast period. For instance, in June 2020, Food and Drug Administration (FDA) has granted fast track designation to TVAX Biomedical, Inc. for TVI-Brain-1, an adoptive T cell therapy for the treatment of glioblastoma multiforme. TVI-Brain-1 (TVAX Biomedical) is an autologous, vaccine-enhanced adoptive T-cell therapy consisting a proprietary vaccine pretreatment to create cancer-specific T cells and an activated antitumor T-cell treatment. The Fast Track Designation was supported by positive Phase 2 clinical data in addition to extensive preclinical and Phase 1 safety studies.

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global brain cancer therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Pfizer Inc., GlaxoSmithKline PLC, Novartis AG, Johnson & Johnson, Merck & Co, Bayer AG, and Bristol-Myers Squibb Company
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global brain cancer therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global brain cancer therapeutics market

Market Segmentation

By Indication Insights (Revenue, USD Mn, 2021 - 2033)
Glioblastoma
Meningioma
Pituitary Tumors
Others
By Treatment Type Insights (Revenue, USD Mn, 2021 - 2033)
Targeted Therapy
Chemotherapy
Immunotherapy
Others
By Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region Insights (Revenue, USD Mn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC
- Israel
- Rest of Middle East
Africa
- North Africa
- Central Africa
- South Africa
Key Players in the Brain Cancer Therapeutics Market
Amgen Inc.
AstraZeneca PLC
Hoffmann-La Roche Ltd
Pfizer Inc.
GlaxoSmithKline PLC
Novartis AG
Johnson & Johnson
Merck & Co
Bayer AG
Bristol-Myers Squibb Company

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Indication
- Market Snapshot, By Treatment Type
- Market Snapshot, Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunity
Impact Analysis
Pipeline Analysis
Regulatory Scenario
Market Trends
Key Developments
Epidemiology
PEST Analysis
Brand Analysis

4. Global Brain Cancer Therapeutics Market, By Indication, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Glioblastoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Meningioma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Pituitary Tumors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)

5. Global Brain Cancer Therapeutics Market, By Treatment Type, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Targeted Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Million)
Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Million)
Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Million)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)

6. Global Brain Cancer Therapeutics Market, By Distribution Channel, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Million)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Million)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Million)

7. Global Brain Cancer Therapeutics Market, By Region, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021 - 2033, (USD Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021 - 2033, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021 - 2033, (USD Mn)
  - U.K.
  - Germany
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021 - 2033, (USD Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021 - 2033, (USD Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Region/Countries, 2021 - 2033, (USD Mn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Heat Map Analysis
Market Share Analysis
- Amgen Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- AstraZeneca PLC
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Hoffmann-La Roche Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Pfizer Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- GlaxoSmithKline PLC
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Novartis AG
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Johnson & Johnson
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Merck & Co
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Bayer AG
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Bristol-Myers Squibb Company
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
  - Analyst Views